Shares of Assembly Biosciences Inc (NASDAQ:ASMB) have received an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $42.50.
Several analysts recently weighed in on the company. ValuEngine raised Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. B. Riley assumed coverage on Assembly Biosciences in a report on Friday, January 5th. They set a “neutral” rating and a $35.00 price target for the company. BidaskClub cut Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Jefferies Group assumed coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research note on Wednesday, November 15th.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $45.04, for a total transaction of $45,040.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 3,000 shares of company stock worth $141,270. Corporate insiders own 19.60% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Strs Ohio increased its stake in Assembly Biosciences by 66.9% during the 3rd quarter. Strs Ohio now owns 22,700 shares of the biopharmaceutical company’s stock worth $792,000 after acquiring an additional 9,100 shares during the period. California Public Employees Retirement System increased its stake in Assembly Biosciences by 118.3% during the 2nd quarter. California Public Employees Retirement System now owns 24,540 shares of the biopharmaceutical company’s stock worth $507,000 after acquiring an additional 13,300 shares during the period. Vanguard Group Inc. increased its stake in Assembly Biosciences by 21.2% during the 2nd quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock worth $12,615,000 after acquiring an additional 107,065 shares during the period. JPMorgan Chase & Co. increased its stake in Assembly Biosciences by 6.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock worth $5,944,000 after acquiring an additional 11,412 shares during the period. Finally, Northern Trust Corp increased its stake in Assembly Biosciences by 221.2% during the 2nd quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock worth $4,033,000 after acquiring an additional 134,513 shares during the period. Hedge funds and other institutional investors own 66.34% of the company’s stock.
Assembly Biosciences (ASMB) traded up $0.91 during trading hours on Friday, reaching $57.50. The company had a trading volume of 139,000 shares, compared to its average volume of 154,013. The firm has a market cap of $1,139.20, a PE ratio of -19.36 and a beta of 0.77. Assembly Biosciences has a 1-year low of $18.60 and a 1-year high of $58.68.
ILLEGAL ACTIVITY NOTICE: “Assembly Biosciences Inc (ASMB) Receives $42.50 Average PT from Analysts” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://ledgergazette.com/2018/03/14/assembly-biosciences-inc-asmb-receives-42-50-average-pt-from-analysts.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.